## GE: GE Aerospace - XLI: Industrials

### Executive Summary

STRENGTH thesis confirmed: MRS_20 at 4.2% in lower entry zone (4.0-10.0%), top 6% cross-sectional ranking. Caution: MRS_5 (-0.2%) diverging from MRS_20, watch for reversal. Outperforming sector by 3.6%. Caution: declining volume (52% of avg), momentum weakening (-1.6% MRS).

- **Horizon:** 5-20 days (swing)
- **Risk Profile:** Moderate - momentum continuation
- **Stop Type:** Fixed 2xATR ($298.65)
- **If Wrong:** Exit if MRS_20 drops below entry zone or breaks stop
- **Invalidation:** MRS_20 exits entry zone or MRS_5 turns negative

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 2, Bearish: 0)

**1. Apollon Wealth Management LLC Increases Stake in GE Aerospace $GE**
- Source: MarketBeat | 20251228T082418 | Bullish | Relevance: 100%
- Apollon Wealth Management LLC significantly increased its stake in GE Aerospace, purchasing an additional 4,107 shares and bringing their total holdings to 27,421 shares valued at $8.249 million. This move comes as GE Aerospace has shown strong financial performance, beating Q3 earnings estimates with EPS of $1.66 and revenue of $11.31 billion, and setting optimistic FY2025 guidance. The stock benefits from a "Moderate Buy" consensus rating among analysts, despite an insider sale by SVP Russell Stokes.

**2. 7 Newly Overvalued Stocks this Week**
- Source: Morningstar | 20251230T020940 | Somewhat-Bearish | Relevance: 91%
- Seven US-listed stocks have recently been deemed overvalued by Morningstar, with their ratings shifting to 1 or 2 stars based on their price relative to fair value estimates and uncertainty ratings. Notable companies among these include GE Aerospace, Wells Fargo, Novartis, Capital One Financial, and EchoStar, all moving to a 2-star rating, while Take-Two Interactive Software is now a 1-star stock. This comes as the overall US stock market is considered slightly overvalued, trading at a 2% premium to its fair value estimate.

**3. GE HealthCare CEO Peter Arduini is forging a new chapter while drawing on Jack Welchâ€™s legacy**
- Source: Fortune | 20251228T110202 | Somewhat-Bullish | Relevance: 73%
- GE HealthCare CEO Peter Arduini discusses leading the company post-spin-off from General Electric, drawing on GE's legacy and Jack Welch's leadership principles while adapting to modern medical technology and digital health landscapes. He highlights the company's significant increase in R&D investment and focus on lean principles, innovation, and global market strategies, particularly in China. Arduini emphasizes authenticity, communication, and empowering employees to live the company's values in his leadership approach.

**4. NextNRG signs MOU with A123 for US-made battery storage systems**
- Source: Investing.com Australia | 20251230T110915 | Somewhat-Bullish | Relevance: 73%
- NextNRG, Inc. announced a Memorandum of Understanding with A123 Systems to deploy US-manufactured battery energy storage systems, aiming to avoid import tariffs and mitigate trade risks. This collaboration will focus on integrating A123's systems into NextNRG's U.S. energy projects and may include evaluating a U.S.-based manufacturing facility. The move aligns with NextNRG's significant revenue growth and strategic initiatives in the burgeoning U.S. battery storage market.

**5. Q3 Earnings Outperformers: Illinois Tool Works (NYSE:ITW) And The Rest Of The General Industrial Machinery Stocks**
- Source: FinancialContent | 20251229T030828 | Bullish | Relevance: 72%
- The general industrial machinery sector had a strong Q3, with revenues beating estimates by 1.6%. Illinois Tool Works (ITW) reported mixed results, with an EPS beat but a slight revenue miss, while Hillenbrand (HI) outperformed expectations significantly. Albany (AIN) had the weakest performance, missing analyst estimates, and Kadant (KAI) showed strong results but weak full-year guidance. GE Aerospace (GE) delivered exceptional performance, beating analyst estimates by a significant margin.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-12 | Citigroup | $386 | $0 | 0% |
| 2025-12-04 | Susquehanna | $350 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-12 | Citigroup | init | Buy |
| 2025-12-04 | Susquehanna | init | Positive |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 3 ($10.00M) |
| Sells | 2 ($2.38M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 45.0% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 4 |

**Top Holders:**
- Vanguard Group Inc: 8.7% (+0.1%)
- Blackrock Inc.: 8.3% (+5.3%)
- FMR, LLC: 5.2% (-9.1%)
- TCI Fund Management : 4.5% (0.0%)
- Capital Internationa: 4.2% (-5.8%)

### Key Risks

1. Valuation stretched: PEG 5.8x requires aggressive growth execution.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 5.75 signals overvaluation risk, limited margin of safety. Forward P/E 43.3x stretched relative to 16% growth. Quality metrics strong (ROE 42%, margin 18%). Balance sheet: $2.2B free cash flow. Insider buying signal ($10.0M), management confidence. Institutional flow bullish (5 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $330.6B |
| Beta | 1.41 |
| 52W Range | $159.36 - $318.06 |
| Short Interest | 1.4% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 5.75 |
| Forward P/E | 43.3 |
| Current P/E | 50.0 |
| YoY Growth | 15.5% |
| EPS Direction | RISING |

### Technicals

MRS_20 deteriorating from 5.8% to 4.2% (-1.6% in 5 days), indicating relative weakness vs NASDAQ. Currently in lower STRENGTH zone (4.0-10.0%), cross-sectional ranking at 93rd percentile. MRS_5 (-0.2%) diverging from MRS_20 - short-term weakness emerging. AM_20 at 4.3% shows strong absolute momentum above own 20MA. Outperforming sector by 3.6pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram positive (2.12), confirming momentum. RSI neutral at 60. Volume at 52% of 20MA suggests lack of conviction. OFD pattern: =DBL (Indecision).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 4.17% (CS: 94) | Strong |
| RSI_14 | 59.6 | Neutral |
| MACD Histogram | 2.12 | Bullish |
| vs SMA20 | 1.042x | Above |
| vs SMA50 | 1.034x | Above |
| vs SMA200 | 1.192x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** STRENGTH

### Trade Setup

- **Entry:** $311.79
- **Stop Loss:** $298.65 (4.2% risk)
- **Target:** $331.50 (R:R method)
- **Risk/Reward:** 1.50:1
- **Target Reasoning:** STRENGTH thesis targets 1.5x risk/reward based on historical edge

### Position Sizing

- **Shares:** 100
- **Position Value:** $31,179.00
- **Portfolio %:** 31.18%
- **Risk Dollars:** $1,320.00
- **Risk Per Trade:** 1.32%
- **Modifiers:** L1 110% | L2 120% | Combined 1.32x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (HIGH) | 1.10x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with balanced risk signals and moderate market participation. VIX at 14.33 indicates calm conditions, while positive yield curve (+59bps) and stable economic data support continued expansion. Year-end positioning and Fed uncertainty create near-term caution, but no systemic risks evident.*

### Earnings

**Next:** 2026-01-22 (Est: $1.42)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.47 | $1.66 | +13.0% |
| 2025Q2 | $1.43 | $1.66 | +16.0% |
| 2025Q1 | $1.27 | $1.49 | +17.5% |
| 2024Q4 | $1.04 | $1.32 | +26.9% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_20*